Pharma & Biotech

Ocugen has quietly reshaped its financial outlook. In May, the company placed $130 million in convertible notes, carrying a 6.75%...

Just five days after a landmark Supreme Court victory, Bayer has opened a second front in its glyphosate saga —...

July is shaping up as a binary-riddled month for the small-cap biopharma. Two weeks after shareholders cast decisive ballots on...

ImmunityBio has become a battleground stock where two opposing forces are digging in. Retail traders have piled into the biotech...

The gulf between operational progress and market perception is rarely wider than at Onco-Innovations these days. The oncology biotech has...

The stock has surged more than 16% over the past month, yet the enthusiasm on Wall Street remains conspicuously muted....

Shares of Outlook Therapeutics have exploded higher since late March, surging roughly 950% after the FDA accepted the company’s regulatory...

The euphoria surrounding Bayer’s landmark victory before the US Supreme Court has propelled its shares to €48.40, a near-38% surge...

Outlook Therapeutics has escaped the threat of expulsion from the Nasdaq Capital Market, but the relief is tempered by a...

BioNTech is simultaneously tightening its belt and opening its wallet, a dual move that signals both caution and ambition as...